What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
about
Systematic review of mammary analog secretory carcinoma of salivary glands at 7 years after description.Mammary Analogue Secretory Carcinoma (MASC) of the salivary gland: A new tumor entity.Newly described salivary gland tumors.Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion.Loxo TRK inhibitor data wows oncologists.The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.Ultrastructural Characterization of Mammary Analogue Secretory Carcinoma of the Salivary Glands: A Distinct Entity from Acinic Cell Carcinoma?Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Mammary Analogue Secretory Carcinoma Presenting as a Cervical Lymph Node Metastasis of Unknown Primary Site: A Case ReportThe Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).Secretory Carcinoma of the Breast.NTRK3 kinase fusions in Spitz tumoursBeyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer.Primary cutaneous secretory carcinoma: A previously overlooked low-grade sweat gland carcinoma.Mammary Analogue Secretory Carcinoma of the Thyroid Mimicking Locally Advanced Papillary Thyroid Carcinoma: A Rare Case Report.Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.Clinical and Morphologic Features of ETV6-NTRK3 Translocated Papillary Thyroid Carcinoma in an Adult Population Without Radiation Exposure.A case of primary secretory carcinoma of the thyroid with high-grade features.Sinonasal Secretory Carcinoma of Salivary Gland with High Grade Transformation: A Case Report of this Under-Recognized Diagnostic Entity with Prognostic and Therapeutic Implications.Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the Salivary Gland.Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms.Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling.Primary and Metastatic Melanoma With NTRK Fusions.Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A/B Loss, Distant Metastasis, and Lack of Sustained Response to Crizotinib.Successful Targeted Therapy of Refractory Pediatric Fusion-Positive Secretory Breast CarcinomaAn Unusual Salivary Gland Tumor Mimicking Papillary Thyroid Carcinoma: Mammary Analog Secretory CarcinomaEntrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
P2860
Q30234982-DBA4FE9D-28B1-4E9D-86BF-F5CC2DD91F97Q30251463-E037A13B-373F-4343-8114-B29A13CB70C4Q34548702-AF5A7B92-5ADC-4A97-B2C8-A2F725A696EBQ37248485-E0B62621-7782-486C-A899-62330A0F72C2Q38634676-38893546-40D5-493A-9711-D04393699224Q38904371-158F02D7-79AB-43DB-BA5D-031E25B8E351Q38956444-FF12CD30-7D50-4494-8668-EB5BB6707C38Q39134464-76803CA7-A99E-462B-B169-973741673B73Q39166808-0027768C-81A1-480A-842C-BC59C0D5F71AQ39245355-628C1C4B-3D52-4D58-B8BB-30B4693EF3FDQ39453298-C3549C0A-0634-40B0-BB51-B16E2292347FQ39831543-2FA6C588-5EE6-467D-8CB7-85F4736ADB35Q40173988-A0DF9B3D-5547-4D34-8F36-F0F280CBB667Q41636361-9C05198D-B7FA-4687-B252-49EDC1B5F6CFQ42016867-265BA4F1-BF1D-4B4D-B8CA-38165FF8586AQ42709455-6AE5CB47-4BA3-4F3E-96C9-65599E6F1C0BQ46512789-610CB4FB-2C05-415D-AFF0-9B08BD419999Q47330432-5D2DB1B1-8993-4A6F-AC09-38B108E1AC87Q47566571-ED3B2D0D-D112-4F16-90F2-4AA8B2341A86Q47601932-413841A0-EE4F-4D64-B8E8-E3B86838C08BQ47878847-66AEF1D9-D6D8-49CA-AF6E-88D37AD28AD3Q48362401-B89EB62D-EC53-4579-9C33-1E932F8208C5Q49588384-3CD6318C-909D-487F-B34A-86B3896C2113Q49643911-D54C7370-353F-40A6-B0A0-5E6BAF622DBDQ50251062-F8F4FC21-A7D5-44BC-B206-B88716EEE104Q50325846-2EA6B0DD-3ABC-4EDF-8A0A-9C1AE8359673Q50526571-F2C0B96E-B3F8-43E5-BE5A-5FAC6E335023Q51040335-4F351FF3-7AE3-4937-B40F-DAB032012F12Q52321854-A3443B7B-D369-4ECB-B7C1-C6546D429825Q52570211-C4BF19B1-08BC-4FD5-A649-624DB4DD9674Q52692152-2C86D68F-624D-48A7-A866-629AA8A129B6Q53740485-17A1E969-8B86-454C-A9D3-110BF56C8969Q57943504-A5A0F0F9-1307-49A7-B0CF-E2397A7CBB3CQ58551278-CDB60CCC-352D-413C-8848-DAC188197665Q58698690-97168432-51F8-40E3-9223-D6D4ED0D57A9
P2860
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
What hides behind the MASC: cl ...... ue secretory carcinoma (MASC).
@ast
What hides behind the MASC: cl ...... ue secretory carcinoma (MASC).
@en
What hides behind the MASC: cl ...... y analogue secretory carcinoma
@nl
type
label
What hides behind the MASC: cl ...... ue secretory carcinoma (MASC).
@ast
What hides behind the MASC: cl ...... ue secretory carcinoma (MASC).
@en
What hides behind the MASC: cl ...... y analogue secretory carcinoma
@nl
prefLabel
What hides behind the MASC: cl ...... ue secretory carcinoma (MASC).
@ast
What hides behind the MASC: cl ...... ue secretory carcinoma (MASC).
@en
What hides behind the MASC: cl ...... y analogue secretory carcinoma
@nl
P2093
P2860
P356
P1433
P1476
What hides behind the MASC: cl ...... ue secretory carcinoma (MASC).
@en
P2093
E C Maneval
J Christiansen
P2860
P304
P356
10.1093/ANNONC/MDW042
P577
2016-02-15T00:00:00Z